Biomarker strategy for a phase 1 study of ORIC-944, a potent and selective allosteric PRC2 inhibitor, in patients with metastatic prostate cancer
作者： Anneleen Daemen , Natalie Yuen , Aleksandr Pankov , Eric A Ariazi , Subhash D Katewa
DOI:
关键词:
摘要: Background1. ORIC-944 Induced Dose-dependent H3K27me3 Reduction in Murine Skin Punch Biopsies In Vivo
oricpharma.com 参考文章(0)